Generali Insurance Asset Management appoints Antonio Pilato as the new Head of Investments

Milan – Generali Insurance Asset Management S.p.A. Società di gestione del risparmio (GIAM), the asset management company of the Generali Group specialized in liability-driven (LDI) solutions, announces the appointment of Antonio Pilato as its new Head of Investments, with immediate effect.

Antonio Pilato was previously GIAM’s Head of Trading & Investment Management Support, a role he held since the company changed name in October 2018. Here, he was responsible for the execution of all the transactions performed on financial markets (Fixed Income, Equity, FX and Derivatives) and the activities related to the subscription and redemption of Funds units.

Prior to this, he had held various management positions in trading desk, portfolio engineering and derivatives in the Generali Group, which he joined in 1998.

Based in Milan and reporting to GIAM CEO Francesco Martorana, Pilato leads a team of more than 50 investment professionals in Paris, Trieste, Cologne and Milan.

A CFA Charterholder, he holds a Master Degree in Economics from Roma Tre University in Rome.

Antonio Pilato is taking over from Francesco Martorana, who held the Head of Investments responsibility ad interim, in addition to his CEO role.

Francesco Martorana, Chief Executive Officer at GIAM, said:

“With this new appointment for one of our key roles, we are continuing to equip GIAM with strong competences for future growth. I am very proud we have found internally the talent and experience we were looking for, promoting a capable professional who has been instrumental in the development of our company so far. I wish Antonio further success in his new role.”

GENERALI INSURANCE ASSET MANAGEMENT APPOINTS ANTONIO PILATO AS THE NEW HEAD OF INVESTMENTS

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
LOAD MORE